| Name | Title | Contact Details |
|---|
VBL Therapeutics (NASDAQ: VBLT) is Phase 3 clinical biotechnology company using the machinery of the body to precisely address disease progression. The company has utilized its proprietary gene targeting and antibody platforms to create a pipeline of exquisite solutions for people with difficult to treat cancers and chronic inflammatory diseases. Our lead oncology candidate is Ofravec (VB-111), a first-in-class, targeted anti-cancer gene-therapy agent with a dual mechanism in development to target solid tumors. Ofravec is currently being studied in the OVAL international Phase 3 registration-enabling clinical trial to treat people with platinum-resistant ovarian cancer. Founded in 2000, VBL is based in Modiin, Israel and has recently opened operations in New York.
Phycotransgenics is a Bloomington, IN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bolt Biotherapeutics is a start-up with compelling technology from Dr. Engleman`s Lab at Stanford University, which demonstrated complete cures in numerous cancer models.
Farmaceutical is a licensed medical marijuana business located in Pennsylvania and Ohio.
Brain TunnelGenix Technologies Corp is a Bridgeport, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.